Souhaitez-vous accéder aux communiqués récents ?

SHANGHAI, April 15, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased...

Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.Obsidian’s lead...

Merakris’ MTX-001 research wins SAWC award; human data show significant wound healing. Phase 2 ongoing with FDA and manufacturing catalysts ahead.

GeneCentric will present new data on its fragmentomics-based ExpressCT™ liquid biopsy technology at AACR 2026.

Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Protein Engineering for Pharmaceutical Biotechnology (July 7th - July 8th, 2026)" training has been added to ResearchAndMarkets.com's...

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Keiretsu Forum-MST will present eleven rigorously vetted, investor-ready companies at the 2026 ACA Innovation Funders Showcase, offering curated deal flow

VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive...